Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities

Table 2 Sensitivity, specificity, positive predictive value, and negative predictive value of each score and marker (L vs I-H)

	FIB-4		FAST		Agile 3+		Agile 4		LSM		M2BPGi
Risk	L	I-H	L	I-H	L	I-H	L	I-H	L	I-H	L	I-H
n	71	120	87	104	96	95	131	60	73	118	102	89
HCC	0	26	10	16	0	26	7	19	4	22	5	21
P value	< 0.01		0.44		< 0.01		< 0.01		< 0.01		< 0.01
Sensitivity		1		0.62		1		0.73		0.85		0.81
Specificity		0.43		0.53		0.58		0.79		0.44		0.62
PPV		0.22		0.17		0.27		0.36		0.19		0.25
NPV		1		0.90		1		0.95		0.95		0.95
EGV	0	25	6	19	0	25	1	24	0	25	1	24
P value	< 0.01		0.02		< 0.01		< 0.01		< 0.01		< 0.01
Sensitivity		1		0.76		1		0.96		1		0.96
Specificity		0.43		0.52		0.58		0.79		0.44		0.61
PPV		0.21		0.19		0.26		0.41		0.21		0.27
NPV		1		0.94		1		0.99		1		0.99

L: Low-risk; I: Intermediate-risk; H: High-risk; HCC: Hepatocellular carcinoma; EGV: Esophagogastric varix; HCC: Hepatocellular carcinoma; EGV: Esophagogastric varices; PPV: Positive predictive value, NPV: Negative predictive value; M2BPGi: Mac2-binding protein glycosylation isomer; FAST: FibroScan-AST; FIB-4: Fibrosis-4; LSM: Liver stiffness measurement.